Market access in pharma is the process of getting an approved drug to the patients who need it, at a price that healthcare systems will pay for. It sits between regulatory approval and real-world patient use, covering everything from pricing and reimbursement negotiations to proving a drug’s value to insurers and governments. A drug can clear every regulatory hurdle and still fail commercially if the market access strategy falls short, because the evidence standards that payers demand are often more rigorous than what regulators require for approval.
The Three Core Elements
Market access rests on three pillars: pricing, reimbursement, and patient access. Pricing is about what level payers (insurers, government health systems, employers) will accept. Reimbursement determines whether and how much those payers will cover. Patient access defines which specific patients are eligible for the therapy once it’s reimbursed. All three are interconnected. A drug priced too high may receive reimbursement only for a narrow subset of patients, while a well-priced drug with strong clinical evidence can achieve broad coverage and faster uptake.
What makes market access distinct from regulatory approval is the type of evidence it requires. Regulatory agencies like the FDA and EMA primarily evaluate whether a drug is safe and effective based on clinical trial data. Payers want all of that plus more: head-to-head comparisons against existing treatments, health economic models showing cost-effectiveness, and real-world outcomes data demonstrating the drug actually delivers value within their healthcare budgets.
Who Decides Whether Patients Get Access
The stakeholder landscape is wide. In the traditional model, a pharmaceutical company only needed to convince regulators that a product was safe and effective. Today, companies must also satisfy the value perceptions of payers, health technology assessment (HTA) bodies, pharmacy benefit managers, hospital formulary committees, and sometimes individual clinicians who control prescribing within institutions.
In the United States, pharmacy benefit managers (PBMs) play an outsized role. They negotiate rebates and price discounts with manufacturers, design formularies (the lists of drugs a health plan covers), set cost-sharing requirements for patients, and process claims. PBMs negotiate rebates in exchange for giving a drug preferred placement on formularies. This creates a dynamic where higher-priced drugs offering larger rebates can sometimes win formulary preference over lower-priced alternatives with smaller rebates. In February 2026, the FTC secured a settlement with Express Scripts over allegations it inflated insulin costs through exactly this kind of rebate-driven competition.
In Europe and many other markets, HTA bodies are the gatekeepers. Organizations like NICE in the United Kingdom, IQWIG in Germany, and HAS in France conduct formal assessments of whether a new drug provides enough clinical benefit and economic value to justify public reimbursement. Starting in January 2025, the European Union began requiring joint clinical assessments for new cancer treatments and advanced therapy products. When a manufacturer submits a marketing authorization application to the European Medicines Agency, it must simultaneously submit clinical data to an HTA secretariat that establishes the scope of a shared assessment across EU member states.
How Drugs Prove Their Value to Payers
Health economics and outcomes research (HEOR) is the discipline that bridges the gap between clinical trial results and payer decision-making. While clinical trials answer “does this drug work?”, HEOR answers “is this drug worth paying for compared to what’s already available?” It provides data on whether treatments work in the specific populations a payer covers and how much of the cost should be reimbursed.
Several global reimbursement agencies formally require this kind of evidence as part of their standard assessment process, including NICE, certain Spanish HTA agencies, the Korean Health Insurance Review Agency, and Thailand’s Health Intervention and Technology Assessment Program. In the United States, pharmaceutical companies typically submit HEOR data through a standardized dossier format developed by the Academy of Managed Care Pharmacy. Surveys of U.S. payer decision-makers show that while safety and efficacy remain the top priorities, 90% consider net cost and head-to-head comparisons very or extremely important, 87% prioritize drug superiority data, and 83% value outcomes evidence.
In practice, this means a pharmaceutical company preparing for launch needs to build economic models showing the long-term cost impact of its drug on a healthcare system, generate comparative data against standard-of-care treatments, and often collect real-world evidence from clinical practice settings to supplement controlled trial results.
When Market Access Work Begins
Market access planning doesn’t start at launch. It typically begins years earlier, during late-stage clinical development. During Phase III trials, when at least 1,000 patients are enrolled to establish safety and efficacy, market access teams are already identifying what evidence payers will need and designing studies to generate it. This might mean including quality-of-life measures in trial protocols, planning for economic substudies, or building health economic models based on emerging clinical data.
After regulatory approval, which alone involves hundreds of thousands of pages of documentation and six to ten months of agency review, the drug enters the market access gauntlet. In many countries, formal HTA submissions follow, each with their own timelines. A drug approved by regulators might not reach patients for months or even years afterward, depending on how quickly pricing and reimbursement negotiations conclude.
Post-launch, the work continues. Regulatory authorities sometimes require Phase IV studies that collect data from real-world clinical practice. These studies evaluate drug interactions, conduct additional safety testing, and are especially important for drugs treating complex conditions, rare diseases, or populations (like pregnant women) that were underrepresented in earlier trials. For market access teams, this real-world data becomes ammunition for expanded reimbursement, broader patient eligibility, or defense against potential coverage restrictions.
Pricing Models and Negotiations
Pharmaceutical pricing has evolved well beyond a company setting a list price. Value-based purchasing contracts, where reimbursement is linked to patient outcomes, have become increasingly common. In these arrangements, a payer and manufacturer agree that the price, amount, or nature of reimbursement depends on how well the drug actually performs in the real world. If patients don’t achieve specified clinical outcomes, the manufacturer may issue refunds or reduce the price.
In the U.S., the Inflation Reduction Act introduced a new dimension to pricing through Medicare drug price negotiation. In August 2023, the Centers for Medicare and Medicaid Services published the first list of 10 Part D drugs selected for negotiation, including widely used medications like Eliquis, Jardiance, Xarelto, Entresto, and Stelara. The negotiated maximum fair prices take effect in 2026, and the program is expected to expand to additional drugs in subsequent years. For market access teams, this represents a fundamental shift: the U.S. government is now a direct price negotiator for some of the highest-revenue drugs on the market.
In Europe, the European Federation of Pharmaceutical Industries and Associations has promoted novel pricing and payment models, including managed entry agreements where a drug receives conditional reimbursement while additional evidence is collected. These arrangements help patients access new treatments sooner while reducing financial risk for payers who are uncertain about long-term value.
The Special Case of Rare Disease Drugs
Orphan drugs, developed for rare diseases, face a unique market access challenge. They carry high development costs spread across small patient populations, which drives prices up. At the same time, they rarely meet traditional cost-effectiveness thresholds. A systematic review of economic evaluations for spinal muscular atrophy treatments found that these drugs were not considered cost-effective in multiple studies using standard benchmarks.
This creates a tension. In the U.S., the commonly used willingness-to-pay threshold has been $50,000 to $100,000 per quality-adjusted life year since 1982, a benchmark that many orphan drugs exceed by a wide margin. When a drug isn’t reimbursed by public or private insurers, patients face significant out-of-pocket costs, often leading to exclusion from treatment entirely. This disproportionately affects patients in lower-income countries, where diagnostic methods for rare diseases are already limited and health professionals may lack sufficient knowledge to identify these conditions.
The question of whether standard cost-effectiveness benchmarks are the right tool for appraising rare disease treatments remains unresolved. Reimbursement policies and willingness-to-pay thresholds vary significantly between countries, influenced by national policies and economic conditions, and no single “gold standard” method exists for evaluating orphan drug value. Many HTA bodies now apply separate frameworks or higher thresholds for rare disease treatments, recognizing that standard economic evaluation can systematically exclude drugs for the smallest, most vulnerable patient populations.
Why Market Access Shapes Drug Development
Strong market access planning can fundamentally alter a drug’s commercial trajectory. Favorable pricing, broad reimbursement, and wide patient access lead to higher revenues, which in turn encourage investment in future drug development. The reverse is equally true: a drug with weak market access evidence may be priced lower, reimbursed narrowly, or adopted slowly, undermining the commercial case for the entire therapeutic program.
This is why market access has moved from a late-stage commercial function to a strategic consideration that influences clinical trial design, target product profiles, and even which diseases pharmaceutical companies choose to invest in. Having a clear market access plan from early development provides a more predictable path to commercial success and helps companies allocate resources toward generating the specific evidence that payers, not just regulators, will demand.